Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India

The estimated prevalence of hepatitis C virus (HCV) infection in India is between 0.5 and 1.5% with hotspots showing much higher prevalence in some areas of northeast India, in some tribal populations and in certain parts of Punjab. Genotype 3 is the most prevalent type of infection. Recent years ha...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical and experimental hepatology 2014-06, Vol.4 (2), p.117-140
Main Authors: Puri, Pankaj, Anand, Anil C, Saraswat, Vivek A, Acharya, Subrat K, Sarin, Shiv K, Dhiman, Radha K, Aggarwal, Rakesh, Singh, Shivaram P, Amarapurkar, Deepak, Arora, Anil, Chhabra, Mohinish, Chetri, Kamal, Choudhuri, Gourdas, Dixit, Vinod K, Duseja, Ajay, Jain, Ajay K, Kapoor, Dharmesh, Kar, Premashis, Koshy, Abraham, Kumar, Ashish, Madan, Kaushal, Misra, Sri P, Prasad, Mohan V.G, Nagral, Aabha, Puri, Amarendra S, Jeyamani, R, Saigal, Sanjiv, Shah, Samir, Sharma, Praveen K, Sood, Ajit, Thareja, Sandeep, Wadhawan, Manav
Format: Article
Language:English
Subjects:
antiviral therapy
chronic hepatitis
Endocrinology & Metabolism
Gastroenterology and Hepatology
hepatitis C virus
INASL Consensus Statement
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The estimated prevalence of hepatitis C virus (HCV) infection in India is between 0.5 and 1.5% with hotspots showing much higher prevalence in some areas of northeast India, in some tribal populations and in certain parts of Punjab. Genotype 3 is the most prevalent type of infection. Recent years have seen development of a large number of new molecules that are revolutionizing the treatment of hepatitis C. Some of the new directly acting agents (DAAs) like sofosbuvir have been called game-changers because they offer the prospect of interferon-free regimens for the treatment of HCV infection. These new drugs have not yet been approved in India and their cost and availability is uncertain at present. Till these drugs become available at an affordable cost, the treatment that was standard of care for the whole world before these newer drugs were approved should continue to be recommended. For India, cheaper options, which are as effective as the standard-of-care (SOC) in carefully selected patients, are also explored to bring treatment within reach of poorer patients. It may be prudent to withhold treatment at present for selected patients with genotype 1 or 4 infection and low levels of fibrosis (F1 or F2), and for patients who are non-responders to initial therapy, interferon intolerant, those with decompensated liver disease, and patients in special populations such as stable patients after liver and kidney transplantation, HIV co-infected patients and those with cirrhosis of liver.
ISSN:0973-6883
2213-3453
DOI:10.1016/j.jceh.2014.06.001